Genetic Polymorphisms in the Host and COVID-19 Infection

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2021 May 11

PMID 33973175

Citations 15

Authors

Joris R Delanghe

Marc L De Buyzere

Marijn M Speeckaert

Affiliations

Soon will be listed here.

Abstract

The outbreak of the COVID-19 pandemic shows a marked geographical variation in its prevalence and mortality. The question arises if the host genetic variation may (partly) affect the prevalence and mortality of COVID-19. We postulated that the geographical variation of human polymorphisms might partly explain the variable prevalence of the infection. We investigated some candidate genes that have the potential to play a role in the immune defense against COVID-19: complement component 3 (C3), galactoside 2-alpha-L-fucosyltransferase 2 (FUT2), haptoglobin (Hp), vitamin D binding protein (DBP), human homeostatic iron regulator protein (HFE), cystic fibrosis transmembrane conductance regulator (CFTR), and angiotensin-converting enzyme 1 (ACE1). In a univariate approach, ACE1 D/I, C3, CFTR, and HFE polymorphisms correlated significantly with COVID-19 prevalence/mortality, whereas Hp and FUT2 polymorphism did not show any significant correlations. In a multivariate analysis, only ACE1 D/I and C3 polymorphisms were determinants for COVID-19 prevalence/mortality. The other polymorphisms (CFTR, DBP, FUT2, HFE, and Hp) did not correlate with COVID-19 prevalence/mortality. Whereas ACE1 D/I polymorphism shows functional links with ACE2 (which is the receptor for the virus) in COVID-19, C3 can act as a critical step in the virus-induced inflammation. Our findings plead against a bystander role of the polymorphisms as a marker for historical migrations, which comigrate with causal genes involved in COVID-19 infection. Further studies are required to assess the clinical outcome of COVID-19 in C3S and ACE1 D allele carriers and to study the role of C3 and ACE1 D/I polymorphisms in COVID-19 and their potential effects on treatment response.

Citing Articles

Investigation of the Relationship between Vitamin D Deficiency and Vitamin D-Binding Protein Polymorphisms in Severe COVID-19 Patients.

Batur L, Dokur M, Koc S, Karabay M, Akcay Z, Gunger E Diagnostics (Basel). 2024; 14(17).

PMID: 39272727 PMC: 11393911. DOI: 10.3390/diagnostics14171941.

The immune inflammation factors associated with disease severity and poor prognosis in patients with COVID-19: A retrospective cohort study.

Kang Y, Lu S, Zhong R, You J, Chen J, Li L Heliyon. 2024; 10(1):e23583.

PMID: 38173531 PMC: 10761779. DOI: 10.1016/j.heliyon.2023.e23583.

Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity.

Tedbury P, Manfredi C, Degenhardt F, Conway J, Horwath M, McCracken C FASEB J. 2023; 37(11):e23220.

PMID: 37801035 PMC: 10760435. DOI: 10.1096/fj.202300077R.

Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know.

Zelek W, Harrison R Immunobiology. 2023; 228(3):152393.

PMID: 37187043 PMC: 10174470. DOI: 10.1016/j.imbio.2023.152393.

Impact of Toll-Like Receptor 2 and 9 Gene Polymorphisms on COVID-19: Susceptibility, Severity, and Thrombosis.

Alhabibi A, Hassan A, Abd Elbaky N, Eid H, Khalifa M, Wahab M J Inflamm Res. 2023; 16:665-675.

PMID: 36825132 PMC: 9942505. DOI: 10.2147/JIR.S394927.

References

Alfonso-Sanchez M, Perez-Miranda A, Garcia-Obregon S, Pena J . An evolutionary approach to the high frequency of the Delta F508 CFTR mutation in European populations. Med Hypotheses. 2010; 74(6):989-92. DOI: 10.1016/j.mehy.2009.12.018. View

Alper C, Propp R . Genetic polymorphism of the third component of human complement (C'3). J Clin Invest. 1968; 47(9):2181-91. PMC: 297379. DOI: 10.1172/JCI105904. View

Barton J, Edwards C, Acton R . HFE gene: Structure, function, mutations, and associated iron abnormalities. Gene. 2015; 574(2):179-92. PMC: 6660136. DOI: 10.1016/j.gene.2015.10.009. View

Borzan V, Tomasevic B, Kurbel S . Hypothesis: Possible respiratory advantages for heterozygote carriers of cystic fibrosis linked mutations during dusty climate of last glaciation. J Theor Biol. 2014; 363:164-8. DOI: 10.1016/j.jtbi.2014.08.015. View

Bradbury J . Ancient footsteps in our genes: evolution and human disease. Gene variants selected during evolution may underlie many common diseases. Lancet. 2004; 363(9413):952-3. DOI: 10.1016/s0140-6736(04)15824-8. View

Bucher J, Boelle P, Hubert D, Lebourgeois M, Stremler N, Durieu I . Lessons from a French collaborative case-control study in cystic fibrosis patients during the 2009 A/H1N1 influenza pandemy. BMC Infect Dis. 2016; 16:55. PMC: 4736161. DOI: 10.1186/s12879-016-1352-2. View

Carroll M . The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol. 1998; 16:545-68. DOI: 10.1146/annurev.immunol.16.1.545. View

Colombo C, Battezzati P, Lucidi V, Magazzu G, Motta V, Alicandro G . Influenza A/H1N1 in patients with cystic fibrosis in Italy: a multicentre cohort study. Thorax. 2011; 66(3):260-1. DOI: 10.1136/thx.2010.157032. View

Colombo C, Burgel P, Gartner S, van Koningsbruggen-Rietschel S, Naehrlich L, Sermet-Gaudelus I . Impact of COVID-19 on people with cystic fibrosis. Lancet Respir Med. 2020; 8(5):e35-e36. PMC: 7159857. DOI: 10.1016/S2213-2600(20)30177-6. View

10.

Damman J, Daha M, Leuvenink H, van Goor H, Hillebrands J, van Dijk M . Association of complement C3 gene variants with renal transplant outcome of deceased cardiac dead donor kidneys. Am J Transplant. 2011; 12(3):660-8. DOI: 10.1111/j.1600-6143.2011.03880.x. View

11.

Delanghe J, Langlois M, Boelaert J, Van Acker J, Van Wanzeele F, van der Groen G . Haptoglobin polymorphism, iron metabolism and mortality in HIV infection. AIDS. 1998; 12(9):1027-32. View

12.

Delanghe J, Speeckaert M, De Buyzere M, Langlois M, Torck M . Human plasma protein polymorphisms and the persistence of cultural diversity. Proc Natl Acad Sci U S A. 2012; 109(43):E2914. PMC: 3491503. DOI: 10.1073/pnas.1211000109. View

13.

Delanghe J, Speeckaert R, Speeckaert M . Complement C3 and its polymorphism: biological and clinical consequences. Pathology. 2013; 46(1):1-10. DOI: 10.1097/PAT.0000000000000042. View

14.

Delanghe J, Speeckaert R, Speeckaert M . Behind the scenes of vitamin D binding protein: more than vitamin D binding. Best Pract Res Clin Endocrinol Metab. 2015; 29(5):773-86. DOI: 10.1016/j.beem.2015.06.006. View

15.

Delanghe J, Speeckaert M, De Buyzere M . The host's angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections. Clin Chim Acta. 2020; 505:192-193. PMC: 7102561. DOI: 10.1016/j.cca.2020.03.031. View

16.

Dhillon N, Walsh L, Kruger B, Mehrotra A, Ward S, Godbold J . Complement component C3 allotypes and outcomes in liver transplantation. Liver Transpl. 2010; 16(2):198-203. DOI: 10.1002/lt.21972. View

17.

Farrell P . The prevalence of cystic fibrosis in the European Union. J Cyst Fibros. 2008; 7(5):450-3. DOI: 10.1016/j.jcf.2008.03.007. View

18.

Ge L, Trujillo G, Miller E, Kew R . Circulating complexes of the vitamin D binding protein with G-actin induce lung inflammation by targeting endothelial cells. Immunobiology. 2013; 219(3):198-207. PMC: 3946638. DOI: 10.1016/j.imbio.2013.10.001. View

19.

Henry S, Oriol R, Samuelsson B . Lewis histo-blood group system and associated secretory phenotypes. Vox Sang. 1995; 69(3):166-82. DOI: 10.1111/j.1423-0410.1995.tb02591.x. View

20.

Kasvosve I, Speeckaert M, Speeckaert R, Masukume G, Delanghe J . Haptoglobin polymorphism and infection. Adv Clin Chem. 2010; 50:23-46. DOI: 10.1016/s0065-2423(10)50002-7. View